High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy
Year: 2024
Type: article
Abstract: Few clinical studies investigated the putative link between the activation of immunogenic cell death (ICD) and the oncological outcome. Recent data, published in a Phase 1b trial, demonstrated that an ICD-associated surge in the plasma concentration of high-mobility group box 1 (HMGB1) indicates favorable prognosis in patients with advanced leiomyosarcomas treated with the combination of doxorubicin, dacarbazine and nivolumab.
Source: OncoImmunology
Authors: Lucillia Bezu, Guido Kroemer
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,913
Funders: Philippe Foundation, Seerave Foundation, Equipex, European Commission, Agence Nationale de la Recherche, Fondation pour la Recherche Médicale, Ligue Contre le Cancer, Centre National de la Recherche Scientifique, Institut Universitaire de France, Institut National Du Cancer, Labex Immuno-Oncology, HORIZON EUROPE European Research Council
Awards: G1056382719, Next-generation phenotypic screening for oncological applications, Coherent Raman Imaging for the Molecular Study of the OrigiN of diseases, G2045273392, Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception., G2786066923, G2980289319, G3231222199, G330243840, G3423759144, G3853421405, G434337789, G4656594441, Immunogenic cell death (ICD) in the cancer-immune dialogue, G7041469554, G7201032678, G82931992, Université de Paris
OpenAlex ID: W4404621877